Abernethy: Scientific advisors struggle with early biotech's short-term focus
Dr. Amy Abernethy · a16z Podcast | Connecting Hearts, Bodies, and Networks to Cure Cancer · Feb 26, 2019 · at 30:12
Dr. Amy Abernethy discusses managing scientific advisor expectations while keeping early bio startups focused on three-to-six-month execution milestones.
0:00 / 0:13exact quote · 13.8s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“Those advisors who are bringing that scientific advice to you, either in your company or as external advisors, are not going to understand why you're not doing all the things that you have to do for that seven year timeframe, because really what you've got to do is focus right now.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Dr. Amy Abernethy
Abernethy: Testing cancer drugs in dogs saves tens of millions per drug
“The whole message that really I walked away from that conference with was that if we now embedded into the drug development process for human drug development a better understanding of how those drugs performed in dogs, we could save many tens of millions of d…”
Abernethy: Lack of pet HIPAA rules simplifies veterinary health data aggregation
“There's no doggy HIPAA. Now, we have to do the right thing by pets and pet owners, and we need to basically only think about using that information in a way that's good for society, for pets and pet owners. But that being said, many of the impediments, as we t…”
Abernethy: Most FDA applications still arrive as static PDF files
“In fact, the way the majority of our applications still come in is through PDFs or sort of essentially large digital representations of what used to come in on trucks.”
Dr. Abernethy: Dogs share more conserved biology with humans than mice do
“So there's much more conserved biology between dog and human than mouse and human.”
Abernethy: Health data platforms must serve clinical users before monetizing data
“So what we saw at Flatiron is you've got to make sure that you take care of oncologists and patients first, and have a mechanism to bring the data in, and then you can get the data ready To have secondary purposes. But if you have that out of order, you've act…”